Key takeaways
- Novo Nordisk's stock has declined over 70% from its peak, prompting investors to demand a strategic roadmap beyond semaglutide.
What happened
Novo Nordisk is facing intense pressure from institutional investors and financial analysts to present a concrete, medium-term strategic roadmap that extends beyond its core blockbuster drug, semaglutide. According to a Reuters report, shareholders are urging the Danish drugmaker’s CEO, Mike Doustdar, to outline plans to diversify into new therapeutic areas and secure acquisitions to counter looming patent expirations and stiff market competition.
Why it matters
For millions of Americans navigating the medical weight-loss market, Novo Nordisk's corporate strategy directly influences the availability, pricing, and variety of treatment options. Semaglutide—the active ingredient in Novo's massive brand-name blockbusters Ozempic and Wegovy—has historically dominated the GLP-1 landscape. However, as the drugmaker faces mounting pressure to look beyond semaglutide, its corporate pivot will dictate how quickly next-generation weight-loss therapies reach the market, how aggressively the company slashes prices to maintain market share, and whether patients will eventually see a surge of cheaper generic options in the 2030s.
What the data says
The financial and clinical data driving this investor anxiety highlights a shifting balance of power in the $100 billion global obesity market:
- Market Capitalization Shifts: Novo Nordisk rode the wave of Wegovy's 2021 launch to become Europe's most valuable listed firm in 2023, peaking with a market capitalization of more than $600 billion. However, Reuters reports that Novo’s share price has since plummeted by more than 70% from its peak.
- The Lilly Deficit: Eli Lilly is rapidly gaining ground. Sales of Lilly's rival weight-loss treatment, Zepbound, are projected to outpace Wegovy by more than $7 billion this year, according to LSEG data.
- The Patent Cliff: Semaglutide's patent protections in the United States and other major markets are set to expire in the early 2030s.
- Clinical Setbacks: Novo recently suffered a blow when it had to halt clinical trials for its experimental heart drug, ziltivekimab, alongside a February trial setback for its highly anticipated next-generation obesity treatment, CagriSema.
- Growth Outlook: In August, Novo adjusted its sales and operating profit growth targets to a range of 0% to minus 6% (at constant exchange rates) compared to 2025, which was an improvement over its previous projection of minus 4% to minus 12%.
How it compares
The current market dynamic places Novo’s semaglutide portfolio in direct competition with Eli Lilly’s tirzepatide (Zepbound and Mounjaro). To preserve its market share before patent protection expires, Novo has relied on newer formulations, such as its oral Wegovy pill, which currently holds a competitive lead over Eli Lilly’s experimental oral treatment, Foundayo.
However, analysts warn that oral semaglutide is only a temporary shield against the patent cliff. While Eli Lilly continues to expand its market share with highly effective dual GIP/GLP-1 receptor agonists, financial experts are urging Novo to prioritize alternative early-stage candidates like zenagamtide. This is increasingly viewed as a safer long-term bet than CagriSema, which has experienced trial volatility.
For cash-paying consumers in the United States, this competitive pressure is a primary driver behind the changing costs of weight-loss care. While brand-name Wegovy carries a list price of roughly $1,349 per month, the high cost and frequent supply constraints have led millions of buyers to seek more affordable routes. Many now use online providers and telehealth platforms to compare their clinical options, frequently choosing compounded vs brand-name semaglutide to bypass high retail prices.
How this fits the bigger picture
This investor backlash is a direct consequence of a broader corporate identity shift at the company. In our previous coverage of how Novo Nordisk rebranded to ‘Novo’, we highlighted how the company is restructuring its corporate image to transition from a traditional diabetes-focused firm into a diversified healthcare giant.
To maintain its competitive edge against Eli Lilly, Novo has also tried to streamline patient access. As we detailed when Novo outlined its direct-to-consumer strategy, the company is attempting to establish direct relationships with US buyers to bypass traditional supply chain hurdles.
However, with investors now demanding acquisitions outside of diabetes and obesity—specifically pointing to cardiovascular and rare diseases—Novo's focus may split. Rather than solely concentrating on making obesity drugs cheaper or more accessible, Novo's capital may increasingly flow toward buying up biotech firms in entirely different clinical fields.
What happens next
To appease Wall Street, CEO Mike Doustdar is expected to lean more heavily on bolt-on acquisitions and external licensing deals to replenish Novo's thinning late-stage pipeline.
For US patients, the immediate future centers on upcoming Phase III clinical trials and key readouts scheduled for next year. The market will closely watch the development of zenagamtide and CagriSema to see if Novo can deliver a successor capable of matching Lilly's clinical efficacy. In the meantime, the impending 2030s patent cliff means that the clock is ticking for Novo to maximize its semaglutide revenue, a reality that will heavily influence its US pricing and insurance negotiation strategies over the next five years.
CompareRx does not provide medical advice. Always consult a licensed healthcare provider before starting any medical weight-loss program or switching medications.